Evidence map›Paper›PMID 37766428›Full record

ArticleBiophysical journal2023

Biophysical phenotype mixtures reveal advantages for tumor muscle invasion in vivo.

Kendra D Marr, Jaime M C Gard, William L Harryman, Elijah J Keeswood, Allan I Paxson, Charles Wolgemuth, Beatrice S Knudsen, Raymond B Nagle, Lori Hazlehurst, Maximiliano Sorbellini and 1 more

Open access · greenAbstract read
In one paragraph

Article in Biophysical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kendra D MarrCancer Biology Graduate Interdisciplinary Program, University of Arizona, Tucson, Arizona; Medical Scientist Training Program, College of Medicine, University of Arizona, Tucson, Arizona.
Jaime M C GardUniversity of Arizona Cancer Center, Tucson, Arizona.
William L HarrymanUniversity of Arizona Cancer Center, Tucson, Arizona.
Elijah J KeeswoodUniversity of Arizona Cancer Center, Tucson, Arizona; Partnership for Native American Cancer Prevention, University of Arizona, Tucson, Arizona.
Allan I PaxsonPartnership for Native American Cancer Prevention, University of Arizona, Tucson, Arizona.
Charles WolgemuthDepartment of Physics, University of Arizona, Tucson, Arizona.
Beatrice S KnudsenDepartment of Pathology, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Raymond B NagleDepartment of Pathology, University of Arizona Cancer Center, Tucson, Arizona.
Lori HazlehurstAssociate Director of Basic Research, Co-Leader Alexander B. Osborn Hematopoietic Malignancy and Transplantation, West Virginia University, Morgantown, West Virginia.
Maximiliano SorbelliniDepartment of Urology, College of Medicine, University of Arizona, Tucson, Arizona.
Anne E CressUniversity of Arizona Cancer Center, Tucson, Arizona; Department of Cellular and Molecular Medicine and Department of Radiation Oncology, College of Medicine, University of Arizona, Tucson, Arizona. Electronic address: cress@arizona.edu.
University of Arizona · USUniversity of Utah · USWest Virginia University · US

Funding

VITAMIN AP30CA023074 · NCI · UNIVERSITY OF ARIZONA · PI Justin M Snider · 1985 to 2026
$110.2M
Uranium as an Environmental Risk Factor for Cancer Among the NavajoU54CA143924 · NCI · UNIVERSITY OF ARIZONA · PI Melissa Marie Herbst-Kralovetz, JUANITA L. MERCHANT · 2009 to 2026
$26.7M
Integrative Cancer Scholars Training GrantT32CA009213 · NCI · UNIVERSITY OF ARIZONA · PI CAREW, JENNIFER S, CURIEL-LEWANDROWSKI, CLARA · 1985 to 2024
$8.6M
Smooth muscle invasion selects for aggressive prostate cancerF30CA247106 · NCI · UNIVERSITY OF ARIZONA · PI MARR, KENDRA DANICE · 2020 to 2023
$179k
NCI NIH HHS F30 CA247106NCI NIH HHS P30 CA023074NCI NIH HHS T32 CA009213NCI NIH HHS U54 CA143924
6 · The paper itself

Abstract

Bladder, colon, gastric, prostate, and uterine cancers originate in organs surrounded by laminin-coated smooth muscle. In human prostate cancer, tumors that are organ confined, without extracapsular extension through muscle, have an overall cancer survival rate of up to 97% compared with 32% for metastatic disease. Our previous work modeling extracapsular extension reported the blocking of tumor invasion by mutation of a laminin-binding integrin called α6β1. Expression of the α6

Indexed as

Extranodal ExtensionLamininAnimalsCell AdhesionHumansIntegrin alpha6MaleMusclesPhenotypeIntegrin alpha6Laminin

Identifiers

PMID37766428
PMCPMC10645557
OpenAlexW4387046568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.